newsfilter
← Latest News
Business Wire·

Clovis Oncology Highlights FAP-2286 Preclinical Data Presented at the Targeted Radiopharmaceuticals Summit

Clovis Oncology, Inc. (NASDAQ:CLVS) announced today's presentation by Andrew D. Simmons, Ph.D., Clovis' Senior Vice President, Translational Medicine, at the 3rd Targeted Radiopharmaceuticals Summit being held virtually December 7-9, 2021. Dr. Simmons'